Click to goto CDHA Public Site Click to goto DivEMS Dal Public Site Click to goto EHS Nova Scotia

Vertigo/Dizziness

Date Last Search Run: Feb 01, 2022
Table last updated: May 02, 2021
Data last added: Jan 26, 2021

Recommendation RECOMMENDATION FOR INTERVENTION
STRENGTH OF EVIDENCE FOR INTERVENTION   SUPPORTIVE (Green) NEUTRAL (Yellow) AGAINST (Red) NOT YET GRADED (White)
1 (strong evidence exists)  
2 (fair evidence exists)      
3 (weak evidence exists)      


Interventions

Antiemetic (Central)
Level Direction Primary Outcome Patient/Process Setting Reference
I Supportive (Green) Severity of vertigo Patient In-Patient Saberi A, Pourshafie SH, Kazemnejad-Leili E, Nemati S, Sutohian S, Sayad-Fathi S. Ondansetron or promethazine: Which one is better for the treatment of acute peripheral vertigo? Am J Otolaryngol 2019; 40(1):10-5. Medline

Dimenhydrinate
Level Direction Primary Outcome Patient/Process Setting Reference
I Supportive (Green) Termination of vertigo Patient ED-MD Marill KA., Walsh MJ., Nelson BK. Intravenous lorazepam versus dimenhydrinate for treatment of vertigo in the emergency department: A randomized clinical trial. Ann Emerg Med 2000; 36(4):310-9. Medline

Lorazepam-IV
Level Direction Primary Outcome Patient/Process Setting Reference
I Neutral (Yellow) Termination of vertigo Patient ED-MD Marill KA., Walsh MJ., Nelson BK. Intravenous lorazepam versus dimenhydrinate for treatment of vertigo in the emergency department: A randomized clinical trial. Ann Emerg Med 2000; 36(4):310-9. Medline

Oxygen
Level Direction Primary Outcome Patient/Process Setting Reference


[ PEP Database - Table of Contents ] [ Email: PEP@Dal.ca ]